Henry Schein

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgicals, diagnostic tests, infection-control products and vitamins. The Technology & Value-Added Services segment offers financial on a non-recourse basis, network and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Henry Schein reports solid Q4 performance and anticipates growth

Henry Schein's Q4 performance showcased growth amidst challenges, with a strategic focus on core margin expansion and strong performance in dental specialties. While facing challenges from declining PPE sales and supply chain issues, the company sees opportunities in stable dental markets and continued growth in operating income. Overall, the company remains optimistic about its outlook for 2023.

Henry Schein reports strong Q1 earnings, eyes growth through acquisitions

Henry Schein's Q1 2023 earnings call highlighted strong financial performance across its dental, medical, and Technology and Value-Added Services businesses. While facing challenges from declining PPE and COVID-19 test kit sales, the company remains optimistic about growth opportunities through acquisitions and stable business segments.

Henry Schein reports solid Q2 results, eyes growth opportunities

Henry Schein's Q2 performance was driven by strong dental sales, while facing challenges from declining PPE and COVID test kit sales. The company is focused on strategic acquisitions and expanding product offerings, with opportunities in technology and specialty products driving growth.

Henry Schein navigates post-cyber incident challenges, focuses on recovery

Henry Schein faced challenges from a cybersecurity incident impacting operations but showcased resilience and recovery efforts across its business segments.
Strategic initiatives focused on customer retention, operational efficiency, and cybersecurity response highlight the company's commitment to long-term growth and stability.
Despite challenges in specific segments and cybersecurity spending variables, Henry Schein's focus on recovery, cost-cutting, and customer trust positions it for future opportunities.
The company's emphasis on digital channels, stable medical demand, and strategic cost-cutting measures underscores its adaptability and strategic vision for sustained growth.

Henry Schein reports resilient Q4 performance and outlines 2024 guidance

Henry Schein's Q4 2023 performance reflects resilience amidst challenges, with a strategic focus on technology, global sales, and recovery post-cyber incident. The company's 2024 outlook includes managing residual cyber impacts and pursuing growth opportunities.

Henry Schein reports solid Q1 earnings, eyes market share expansion

Henry Schein's Q1 performance reflects resilience and growth across key segments, with a focus on market share expansion and profitability. While facing challenges in dental consumables and pricing stability, the company is leveraging opportunities in product portfolio expansion and market positioning. Strategic acquisitions and recovery efforts post-cyber incident are driving competitive strength and customer loyalty.

Henry Schein reports mixed Q2 performance, focuses on cost savings

Henry Schein navigated challenges from a cyber incident, with mixed performance across segments in Q2 2024.
Strong sales growth in dental specialties, focus on cost savings, and resilience in technology services were highlights.
The company's strategic initiatives, financial guidance update, and confidence in future prospects were key takeaways from the call.

Henry Schein excels in Q3 with strategic growth initiatives

Henry Schein's Q3 performance reflects strong market positioning and strategic execution, driving growth across key business segments.
While facing challenges such as LCI sales decline, the company's focus on operational efficiency and cost management remains a priority.
With increased sales guidance, ongoing restructuring initiatives, and strategic capital allocation plans, Henry Schein is poised for continued success and expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins. The Technology and Value-Added Services segment offers financial on a non-recourse basis, network, and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.

MELVILLE, N.Y.--(BUSINESS WIRE)--In celebration of Earth Day 2023, Henry Schein, Inc. (Nasdaq: HSIC) today announced the launch of Practice Green – a global initiative designed to encourage health care practitioners to become more eco-friendly – in the U.S. and Canada. Practice Green aims to help empower the health care community to establish sustainable practices for a healthier planet.

Henry Schein Champions Sustainable Business Practices With the Launch of Practice Green in North America

Crocs

Graphic Packaging Hld

CROX, HSIC and and GPK made it to the Zacks Rank #1 (Strong Buy) growth stocks list on April 13, 2023.

Best Growth Stocks to Buy for April 13th

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) today announced its support for the Carry The Load® Memorial May campaign, a month-long Memorial Day awareness program providing active ways to connect Americans to the sacrifices made by the U.S. military, Veterans, first responders, and their families.

Henry Schein Announces Its Support for the ‘Carry The Load®' Memorial May Campaign for the Second Year in a Row

Henry Schein (HSIC) announces that the completion of the Biotech Dental partnership brings forth the company's several important solutions to customers.

Henry Schein (HSIC) Acquires Majority Stake in Biotech Dental

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein Medical, the U.S. medical business of Henry Schein, Inc. (Nasdaq: HSIC), announced Gina Harris, Head Athletic Trainer at Bellport High School in Brookhaven, New York, as the winner of the third annual Henry Schein Medical Athletics and Schools Rising Star Award. The award celebrates emerging athletic trainers with one to five years of experience in the Sports Medicine industry.

Henry Schein Medical Announces Winner of Its 2023 Rising Star Award Program

Asure Software

Ralph Lauren

ASUR, RL and HSIC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on April 6, 2023.

Best Growth Stocks to Buy for April 6th

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein completes strategic partnership with Biotech Dental Group.

Henry Schein Completes Strategic Partnership With Biotech Dental Group

Align Technology

HSIC vs. ALGN: Which Stock Is the Better Value Option?

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) announced its presence at the 2023 ADSO Annual Summit, including thought-leadership presentations on the future of dentistry and intrapreneurship as well as activities to support communities in need.

Henry Schein Announces Presence at the 2023 Association of Dental Support Organizations (ADSO) Summit

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Henry Schein (HSIC) Stock Undervalued Right Now?

Medtronic

Stryker

Syneos Health

MedTech player like Medtronic (MDT) are integrating artificial intelligence (AI) capabilities to aid therapeutic and diagnostic applications.

MedTech Bigwigs in Spotlight as AI Revolutionizes Healthcare

MELVILLE, N.Y.--(BUSINESS WIRE)--In collaboration with the Association of Dental Support Organizations (ADSO), Henry Schein, Inc. (Nasdaq: HSIC) today announced that it will present a pre-conference program on Tuesday, March 28 from 2:30 – 5:30 pm at the 2023 ADSO Annual Summit.

Henry Schein to Host Pre-conference Program at the 2023 ADSO Annual Summit

Henry Schein (HSIC) integrates AI-enabled solutions, Dentrix Ascend Detect AI and Dentrix Ascend Voice, into its cloud-based dental software.

Henry Schein (HSIC) Bolsters Dental Practices With AI Tools

AMERICAN FORK, Utah--(BUSINESS WIRE)--Henry Schein One, a joint venture of Henry Schein Inc. and Internet Brands, has reinforced their commitment to helping dental practices harness the power of Artificial Intelligence (AI) by fully integrating AI solutions into Dentrix Ascend, the Company's cloud-based practice management software. These solutions include Dentrix® Ascend Detect AI powered and manufactured by VideaHealth, and Dentrix Ascend Voice, powered by Bola AI.

Henry Schein One Announces Availability of AI Solutions for Dentrix Ascend

Henry Schein (HSIC) joined ASCA as part of its commitment to augment the value of ambulatory surgery centers.

Henry Schein (HSIC) Aids Growth of Ambulatory Surgery Centers

Henry Schein's (HSIC) distribution business boasts a wide global footprint with 61 distribution centers.

Henry Schein (HSIC) International Growth Solid, Dental Rebounds

Arch Capital

Baidu

Kroger

Toll Brothers

Here are five stocks that pass our screening criteria. These are HSIC, KR, BIDU, TOL and ACGL.

5 Discounted Value Picks Based on PEG Ratio

Ameriprise Financial

HSBC Holdings

Microchip Technology

Everest RE Group

We have narrowed the search to select five companies that have strong potential for 2023. These are: AMP, RE, MCHP, HSIC and HSBC.

Fed May Stick to 25 bps Rate Hike After SVB Fiasco: 5 Picks

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) today announced that it will showcase its comprehensive solutions and provide its perspective on the future of dentistry at the 2023 International Dental Show (IDS) in Cologne, Germany. Henry Schein will present its solutions from 14 to 18 March 2023 at the Koelnmesse in Hall 4.1, Stand A-090. What follows is a summary of the Company's presence at IDS.

Henry Schein Will Showcase a Selection of the Company's Comprehensive Solutions for Oral Health Professionals at International Dental Show 2023

Henry Schein is a significant player in the healthcare industry and has proven in the last earnings report they are capable of increasing revenues despite certain headwinds. Apart from a growing industry and with competent management, the value the company could create for shareholders is definitely there to justify a bull case.

Henry Schein: Competitive Positioning Makes It A Compelling Buy

West Pharmaceutical Services

HSIC vs. WST: Which Stock Is the Better Value Option?

HSIC or WST: Which Is the Better Value Stock Right Now?

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, has been recognized by Ethisphere, a global leader in defining and advancing the standards of ethical business practices, as one of the 2023 World's Most Ethical Companies. Henry Schein has been recognized 12 times and is the only honoree in the Healthcare Products industry.

Ethisphere Names Henry Schein as One of the 2023 World's Most Ethical Companies® for the 12th Consecutive Year

Is Henry Schein (HSIC) a Great Value Stock Right Now?

Lantheus Holdings

There is always an essential need for healthcare and here are two Zacks Rank #1 (Strong Buy) medical stocks that investors should consider buying right now.

News for Henry Schein Stock (HSIC)